Latest Post

March 6, 2018no comments

Cult of Crystallography

Biological macromolecules, such as proteins and DNA, are very small and very complex. It is something of a technological miracle, therefore, that we can visualise their three-dimensional structures at atomic resolution. The first, and still by far the dominant, method of solving these structures is crystallography.

The principal is simple: by packing many millions of molecules into a repeating crystal lattice, the diffraction pattern of X-rays passing through the crystal captures information about the structure of the individual molecules. In effect, the structural information from m...

Read More

Tweets

@JohnTuckerPhD But RWE studies tend to be much larger and cheaper because you are only watching what you were doing… https://t.co/Rxgh61BfdU
- Saturday Jul 21 - 12:57pm

@JohnTuckerPhD Worse than that as effect size will likely be diluted too. RWE not better than RCT - they just answe… https://t.co/AGaFsPu1ty
- Saturday Jul 21 - 12:56pm

SCIENTIFIC SUPPOSITIONS

Contact DrugBaron and Subscribe for a weekly digest of new postsNews, musings & opinions from the pen of the Drug Baron, Cambridge

Drug Baron Blog

Latest Post

March 6, 2018 no comments

Cult of Crystallography

Biological macromolecules, such as proteins and DNA, are very small and very complex. It is something of a technological miracle, therefore, that we can visualise their three-dimensional structures at atomic resolution. The first, and still by far the dominant, method of solving these structures is crystallography.

The principal is simple: by packing many millions of molecules into a repeating crystal lattice, the diffraction pattern of X-rays passing through the crystal captures information about the structure of the individual molecules. In effect, the structural information from many identical molecules amplifies the signal to the point where it can be read and decoded.

This ability to see the structures of individual protein molecules was a huge breakthrough in biology. It may not be as famous as the DNA double helix, but the first protein structure, earned a Nobel prize for Max Perutz in 1962, the same year that Watson, Crick and Wilkins were honoured for solving the DNA structure by the same crystallographic technique.

In the intervening six decades, many thousands of protein structures have been solved in this way, and delivered mechanistic insight into the many functions of proteins, as structural components, molecular motors, enzymes, synthetic factories and signalling networks. They have underpinned the development of numerous drugs, designed to bind in highly specific ways to particular proteins. Today, variations on a theme even allow us to visualise structures of membrane-bound proteins that traditionally eluded crystallisation.

So great has been the positive impact of having a window on these ultra-microscopic structures that its hard to imagine that the ubiquitous application of crystallography has had a unintended negative consequence for our understanding of biology.

Structures obtained using these methods that average across millions of molecules are so embedded in our thinking that we accept them as representative of the protein in vivo, almost without thinking, and certainly without constantly bearing in mind the single biggest assumption of crystallography: that all the molecules are the same.

Together with the cult of DNA centricity, this cult of crystallography has led to a very distorted view of what we think of as a protein. When we name a protein, such as apolipoprotein E (one of DrugBaron’s favorite proteins), the implicit assumption is that we refer to a homogeneous population of molecules, all with the same primary sequence (that is, the same amino acid building blocks in the same order, exactly as encoded by the DNA sequence of the apoE gene) and all with the same three-dimensional structure and conformation …

More

Yearly Archive

Useful Resources

Discovering and developing drugs according to the “asset-centric” strategy depends entirely on the availability of high quality out-sourced service providers, who not only deliver the R&D infra-structure for small and virtual biotech companies, but who understand the essential differences between “asset-centric” R&D and the classical model. DrugBaron has founded and worked for more than a dozen asset-centric companies over the last decade, developing both small molecules and biologics in a wide range of indications. That experience has identified those service providers (usually smaller than the global brands) who understand “asset-centric” R&D and who can support new companies adopting this strategy.  Those are the companies listed here.

The Cambridge Partnership is the only professional services company in the UK exclusively dedicated to supporting companies in the biotechnology industry. We specialize in providing a “one-stop shop” for accountancy, company secretarial, IP management and admin services.

Accounting & Back-Office Services

A professional services company exclusively dedicated to supporting companies within the biotechnology industry.

RxCelerate Ltd is an outsourced drug development platform based near Cambridge, UK. We specialize in delivering an entire road map of drug development services from discovery and medicinal chemistry through to preclinical and clinical Phase IIa.

Out Sourced Drug Developer

Specialising in delivering an entire road map of drug development services from discovery through to preclinical/clinical Phase IIa.

SEND & SUBSCRIBE

Contact DrugBaron and Subscribe for a weekly digest of new posts

Contact Us

EMAIL
drugbaron@rxcelerate.com

RxCelerate UK
Babraham Research Campus
Babraham
Cambridge CB22 3AT
United Kingdom